Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy
Biological drugs with gene and cell therapy potentials, including natural or rationally created biomacromolecules, recombinant proteins/enzymes, gene-carrying DNA/RNA fragments, oncolytic viruses, plasmid and viral vectors or other gene delivering vehicles with specific therapeutic genes and gene ma...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | BBA Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667160325000146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229901739687936 |
|---|---|
| author | Quan-en Yang Nicole Lee Nicole Johnson Jennifer Hong Jenny (Qinghua) Zhao Xiulian Sun Jian Zhang |
| author_facet | Quan-en Yang Nicole Lee Nicole Johnson Jennifer Hong Jenny (Qinghua) Zhao Xiulian Sun Jian Zhang |
| author_sort | Quan-en Yang |
| collection | DOAJ |
| description | Biological drugs with gene and cell therapy potentials, including natural or rationally created biomacromolecules, recombinant proteins/enzymes, gene-carrying DNA/RNA fragments, oncolytic viruses, plasmid and viral vectors or other gene delivering vehicles with specific therapeutic genes and gene manipulation tools, and genetically modified and reprogrammed human cells comprise a large fraction of drug development candidates in modern precision and regeneration medicine. These drugs have displayed unique capabilities in treating patients with previously incurable diseases. However, most of the drug preparations have complex multimolecular structures and require specific biomanufacturing systems and many other additional biological active materials for drug synthesis, cell expansion, and production enhancement. Thus, the final products would have to be subjected to sequential extensive purification processes to exclude impurities and to concentrate the drug products after manufacturing. The quality evaluation for each drug product is an individualized process and must be specifically designed and performed according to the characteristics of the drug and its manufacturing and purification methods. Some of the Quality Control (QC) assays may be very costly and time-consuming, frequently with inconsistent test results from batch-to-batch. This review focuses on QC assessment strategy development for common gene and cell therapy drugs which use prokaryotic or eukaryotic cells for manufacturing or cell factories for in vitro expansions, especially for drug identification and concentration determination, impurity detection and quantification, drug potency, stability, and safety evaluations; and discusses some key issues for drug quality assessments in different categories and emphasizes the importance of individualized QC strategy design. |
| format | Article |
| id | doaj-art-dbd9c1fbf10e43c0af8636dc96189eaa |
| institution | OA Journals |
| issn | 2667-1603 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | BBA Advances |
| spelling | doaj-art-dbd9c1fbf10e43c0af8636dc96189eaa2025-08-20T02:04:01ZengElsevierBBA Advances2667-16032025-01-01710015110.1016/j.bbadva.2025.100151Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapyQuan-en Yang0Nicole Lee1Nicole Johnson2Jennifer Hong3Jenny (Qinghua) Zhao4Xiulian Sun5Jian Zhang6uBriGene Biosciences, Inc., Germantown, MD, USA; Forecyte Biosciences, Inc., Frederick, MD, USA; Corresponding authors.WZ Biosciences Inc., Rockville, MD, USAForecyte Biosciences, Inc., Frederick, MD, USAVigene Biosciences, Inc., Rockville, MD, USAuBriGene Biosciences, Inc., Germantown, MD, USA; Forecyte Biosciences, Inc., Frederick, MD, USAuBriGene Biosciences, Inc., Germantown, MD, USAWZ Biosciences Inc., Rockville, MD, USA; Corresponding authors.Biological drugs with gene and cell therapy potentials, including natural or rationally created biomacromolecules, recombinant proteins/enzymes, gene-carrying DNA/RNA fragments, oncolytic viruses, plasmid and viral vectors or other gene delivering vehicles with specific therapeutic genes and gene manipulation tools, and genetically modified and reprogrammed human cells comprise a large fraction of drug development candidates in modern precision and regeneration medicine. These drugs have displayed unique capabilities in treating patients with previously incurable diseases. However, most of the drug preparations have complex multimolecular structures and require specific biomanufacturing systems and many other additional biological active materials for drug synthesis, cell expansion, and production enhancement. Thus, the final products would have to be subjected to sequential extensive purification processes to exclude impurities and to concentrate the drug products after manufacturing. The quality evaluation for each drug product is an individualized process and must be specifically designed and performed according to the characteristics of the drug and its manufacturing and purification methods. Some of the Quality Control (QC) assays may be very costly and time-consuming, frequently with inconsistent test results from batch-to-batch. This review focuses on QC assessment strategy development for common gene and cell therapy drugs which use prokaryotic or eukaryotic cells for manufacturing or cell factories for in vitro expansions, especially for drug identification and concentration determination, impurity detection and quantification, drug potency, stability, and safety evaluations; and discusses some key issues for drug quality assessments in different categories and emphasizes the importance of individualized QC strategy design.http://www.sciencedirect.com/science/article/pii/S2667160325000146Biological drug quality assessmentBiosimilarCar-t therapyCell and gene therapyDrug potencyDrug purity analysis |
| spellingShingle | Quan-en Yang Nicole Lee Nicole Johnson Jennifer Hong Jenny (Qinghua) Zhao Xiulian Sun Jian Zhang Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy BBA Advances Biological drug quality assessment Biosimilar Car-t therapy Cell and gene therapy Drug potency Drug purity analysis |
| title | Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy |
| title_full | Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy |
| title_fullStr | Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy |
| title_full_unstemmed | Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy |
| title_short | Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy |
| title_sort | quality assessment strategy development and analytical method selection of gmp grade biological drugs for gene and cell therapy |
| topic | Biological drug quality assessment Biosimilar Car-t therapy Cell and gene therapy Drug potency Drug purity analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2667160325000146 |
| work_keys_str_mv | AT quanenyang qualityassessmentstrategydevelopmentandanalyticalmethodselectionofgmpgradebiologicaldrugsforgeneandcelltherapy AT nicolelee qualityassessmentstrategydevelopmentandanalyticalmethodselectionofgmpgradebiologicaldrugsforgeneandcelltherapy AT nicolejohnson qualityassessmentstrategydevelopmentandanalyticalmethodselectionofgmpgradebiologicaldrugsforgeneandcelltherapy AT jenniferhong qualityassessmentstrategydevelopmentandanalyticalmethodselectionofgmpgradebiologicaldrugsforgeneandcelltherapy AT jennyqinghuazhao qualityassessmentstrategydevelopmentandanalyticalmethodselectionofgmpgradebiologicaldrugsforgeneandcelltherapy AT xiuliansun qualityassessmentstrategydevelopmentandanalyticalmethodselectionofgmpgradebiologicaldrugsforgeneandcelltherapy AT jianzhang qualityassessmentstrategydevelopmentandanalyticalmethodselectionofgmpgradebiologicaldrugsforgeneandcelltherapy |